bpc 157 spray Peptide BPC-157 Peptide Pure Oral BPC-157 PURE Oral Spray |

Theoretical and Class-Level Risks These have not been confirmed in cagrilintide trials but are flagged because they appear in related amylin or GLP-1 class data: pancreatitis, gallbladder disease, severe hypoglycemia (mainly when combined with insulin or sulfonylureas), and acute kidney injury secondary to dehydration from severe nausea or vomiting

The drug is recommended only when its benefits outweigh fetal or maternal health risks

These studies span rodents and rabbits

Adverse effects associated with BPC-157 are minimal, with only mild and temporary discomfort reported at the injection site or minor gastrointestinal disturbances in some cases

Cloudiness is often a sign of bacterial contamination or that the peptide has begun to degrade and fall out of solution